Earnings release · INCY
Incyte Reports Third Quarter 2026 Financial Results and Provides Business Updates
Incyte Corp. · Filed · SEC Form 8-K, Item 2.02
Revenue
$1.32 billion
+14% vs a year ago
EPS
—
not detected
Guidance
raisedoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete.
Please read the original before relying on any figure. Not investment advice.
Why it matters
Revenue grew 14% year on year to $1.32 billion. The company lifted its guidance, which is usually read as management's view of coming periods improving.
Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.
What the company states
Revenue
$1.32 billion +14% vs a year ago
…otal revenue of $1.56 billion and total net sales of $1.32 billion in the third quarter of 2026, each an increase of 14% compared to the third quarter of 2025.…
Guidance
Guidance raised
…Raising 2026 full year financial guidance for Opzelura net sales, Hematology and Oncology net sales and total net sales. | Incyte is raising its full year 2026 net sales guidance for Opzelura to $1,100 - $1,120 million, Hematology and Oncology to $890 - $910 million and total net…
Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.